Cost–consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK
Open Access
Abstract
Objectives The objective of this study was to model the clinical and economic impact of adapting current clinical practice in the management of patients with chronic obstructive pulmonary disease (COPD) to treatment according to national and international guideline recommendations. Design Treatment mapping was undertaken to hypothetically redistribute patients from current clinical practice, representing actual prescribing patterns in the UK, to an alternative recommendation-based treatment scenario, representing prescribing in accordance with either National Institute for Health and Care Excellence (NICE) guidance [NG115] or Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 strategy. Setting Primary care practices in the UK (1-year time horizon). Participants Adults with COPD undergoing long-acting inhaler maintenance therapy in the UK (N=1 067,531). Interventions Inhaler maintenance therapy. Outcome measures Costs and clinical outcomes (type of treatment, rates of moderate and/or severe exacerbations, and mild-to-moderate and/or severe pneumonia events) were modelled for the two alternative pathways. Results Compared with current clinical practice, treating patients according to NICE guidance resulted in an estimated annual reduction in expenditure of £46.9 million, and an estimated annual reduction in expenditure of over £43.7 million when patients were treated according to GOLD 2020 strategy. Total cost savings of up to 8% annually could be achieved by treatment of patients according to either of these recommendations. Cost savings arose from a reduction in the rates of pneumonia, with an associated decrease in costs associated with antibiotic use and hospitalisation. Savings were achieved overall despite a small increase in the rate of exacerbations due to the redistribution of certain patients currently undergoing triple inhaled therapy to therapies not containing inhaled corticosteroids. Conclusion Redistribution of patients with COPD from current clinical practice to treatment according to published recommendations would provide substantial cost savings over the first year.Keywords
Funding Information
- Boehringer Ingelheim, Ingelheim am Rhein, Germany (Not applicable)
This publication has 24 references indexed in Scilit:
- Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2017
- S32 Epidemiology of chronic obstructive pulmonary disease (COPD) in the uk: findings from the british lung foundation’s ‘respiratory health of the nation’ projectThorax, 2016
- Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialThe Lancet Respiratory Medicine, 2016
- Inhaled corticosteroids and the increased risk of pneumonia: what’s new? A 2015 updated reviewTherapeutic Advances in Respiratory Disease, 2016
- A review of national guidelines for management of COPD in EuropeEuropean Respiratory Journal, 2016
- The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInternational Journal of Chronic Obstructive Pulmonary Disease, 2015
- Continuing to Confront COPD International Physician Survey: physician knowledge and application of COPD management guidelines in 12 countriesInternational Journal of Chronic Obstructive Pulmonary Disease, 2014
- Converting an odds ratio to a range of plausible relative risks for better communication of research findingsBMJ, 2014
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Long-term Use of Inhaled Corticosteroids and the Risk of Pneumonia in Chronic Obstructive Pulmonary DiseaseArchives of internal medicine (1960), 2009